XK469, a selective topoisomerase IIbeta poison.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1999-10-12

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/PNAS.96.21.12168PMID 10518594PMCID PMC18430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

  2004cited by this paper
• Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.

  1999cited by this paper
• Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents

  1998cited by this paper
• Merbarone Inhibits the Catalytic Activity of Human Topoisomerase IIα by Blocking DNA Cleavage*

  1998cited by this paper
• Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.

  1998cited by this paper
• Eukaryotic DNA topoisomerase IIβ

  1998cited by this paper
• Absence of Topoisomerase IIβ in an Amsacrine-resistant Human Leukemia Cell Line with Mutant Topoisomerase IIα

  1998cited by this paper
• Eukaryotic DNA topoisomerase II beta.

  1998cited by this paper
• Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents.

  1998cited by this paper
• The involvement of topoisomerase I in the induction of DNA-protein crosslinks and DNA single-strand breaks in cells of ultraviolet-irradiated human and frog cell lines.

  1997cited by this paper
• Inhibition of topoisomerase II by liriodenine.

  1997cited by this paper
• Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.

  1997cited by this paper
• Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).

  1996cited by this paper
• Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.

  1996cited by this paper
• Antitopoisomerase drug action and resistance.

  1996cited by this paper
• New in vitro screening model for the discovery of antileukemic anticancer agents.

  1996cited by this paper
• Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.

  1995cited by this paper
• Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines

  1995cited by this paper
• Mechanisms of resistance to topoisomerases poisons.

  1995cited by this paper
• Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.

  1994cited by this paper
• Anticancer Drug Discovery and Development: Natural Products and New Molecular Models

  1994cited by this paper
• Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes.

  1992cited by this paper
• Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.

  1991cited by this paper
• Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.

  1991cited by this paper
• Topoisomerase II levels during granulocytic maturation in vitro and in vivo.

  1991cited by this paper
• Rapid evaluation of topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo.

  1990cited by this paper
• Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

  1989cited by this paper
• Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

  1988cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Selective extraction of polyoma DNA from infected mouse cell cultures.

  1967cited by this paper

• Improved clearance predictions for aldehyde oxidase substrates using a novel triculture human hepatocyte model.

  2025cites this paper
• Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage

  2024influential citation
• New quinoxaline‐piperazine‐oxazole conjugates: Synthesis, in vitro anticancer, in silico ADMET, and molecular docking studies

  2024cites this paper
• New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.

  2024cites this paper
• -Proline catalyzed synthesis of biologically promising heterocycles under sustainable conditions

  2024cites this paper
• GAS2 Upregulation Is a Targetable Vulnerability in Chronic Myeloid Leukemia

  2024cites this paper
• Recent advances on quinoxalines as target‐oriented chemotherapeutic anticancer agents through apoptosis

  2024cites this paper
• One‐Pot Three‐Component Synthesis of Biologically Promising Indenoquinoxaline Fused Spiroheterocycles Starting from 11H‐indeno[1,2‐b]quinoxalin‐11‐ones

  2024cites this paper
• Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase IIβ in Human Leukemia K562 Cells: Generation of a Resistance Phenotype

  2024cites this paper
• Virtual screening and multilevel precision-based prioritisation of natural inhibitors targeting the ATPase domain of human DNA topoisomerase II alpha

  2023cites this paper
• Design and Synthesis of Some New Quinoxaline-1,2,4-Oxadiazole-Amide Conjugates as EGFR Targeting Agents and ADMET Studies

  2023cites this paper
• Synthesis of Morpholine-, Piperidine-, and N-Substituted Piperazine-Coupled 2-(Benzimidazol-2-yl)-3-arylquinoxalines as Novel Potent Antitumor Agents.

  2022cites this paper
• Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents

  2022cites this paper
• Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase IIβ Expression in Human Leukemia K562 Cells with Acquired Resistance to Etoposide

  2022cites this paper
• Design and synthesis of quinoxaline-1,3,4-oxadiazole hybrid derivatives as potent inhibitors of the anti-apoptotic Bcl-2 protein.

  2020cites this paper
• Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing.

  2020cites this paper
• Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II

  2019cites this paper
• Synthesis and Antimicrobial Activity of Some New Substituted Quinoxalines

  2019cites this paper
• Inhibition of a Selective SWI/SNF Function Synergizes with ATR Inhibitors in Cancer Cell Killing

  2019cites this paper
• Pd/PTABS: Low Temperature Etherification of Chloroheteroarenes.

  2018cites this paper
• N-Picolinamides as ligands in Ullman type C–O coupling reactions

  2017cites this paper
• Molecular basis for the DNA damage induction and anticancer activity of asymmetrically substituted anthrapyridazone PDZ-7

  2017cites this paper
• Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells

  2017cites this paper
• Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons

  2017cites this paper
• Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan–Meier plotter

  2017cites this paper
• Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases

  2016cites this paper
• Design, synthesis, biological evaluation and molecular docking study on peptidomimetic analogues of XK469.

  2016cites this paper
• Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions

  2016cites this paper
• A “Double-Edged” Scaffold: Antitumor Power within the 
Antibacterial Quinolone

  2016cites this paper
• Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.

  2016cites this paper
• Quinoxalines Potential to Target Pathologies.

  2015cites this paper
• Salicylate, a Catalytic Inhibitor of Topoisomerase II, Inhibits DNA Cleavage and Is Selective for the α Isoform

  2014influential citation
• Ultrasensitive isolation, identification and quantification of DNA–protein adducts by ELISA-based RADAR assay

  2014cites this paper
• DNA Damaging Drugs

  2014cites this paper
• A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.

  2014cites this paper
• Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity.

  2014cites this paper
• Nicotine Mediates Hypochlorous Acid-Induced Nuclear Protein Damage in Mammalian Cells

  2014cites this paper
• Drugging topoisomerases: lessons and challenges.

  2013cites this paper
• Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

  2012cites this paper
• Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy.

  2012cites this paper
• Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents

  2012cites this paper
• DNA topoisomerase IIβ: a player in regulation of gene expression and cell differentiation.

  2012cites this paper
• Topoisomerase II Inhibitors: Chemical Biology

  2012cites this paper
• Interaction of small molecules with nucleic acid targets: From RNA secondary structure to the ribosome

  2012cites this paper
• Genotoxicity of dietary, environmental and therapeutic topoisomerase II poisons is uniformly correlated to prolongation of enzyme DNA residence.

  2011cites this paper
• The quinoxaline anti‐tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

  2011cites this paper
• Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin.

  2011cites this paper
• Phase I studies

  2010cites this paper
• Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors.

  2010cites this paper
• Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.

  2010cites this paper
• Alternariol acts as a topoisomerase poison, preferentially affecting the IIalpha isoform.

  2009cites this paper
• A study of photodynamic damage to the DNA replication system

  2009cites this paper
• Nuclear targets of photodynamic tridentate ruthenium complexes.

  2009cites this paper
• The Chemotherapeutic Agents XK469 (2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-Bromo-2-quinolinyl)oxy]phenoxy}propionic acid) Inhibit Cytokinesis and Promote Polyploidy and Induce Senescence

  2009cites this paper
• R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

  2009cites this paper
• Depletion and mutation of topoisomerase II in animal cells.

  2009cites this paper
• [TDAE strategy applied to drug-candidate synthesis].

  2008cites this paper
• A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

  2008cites this paper
• NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*

  2008cites this paper
• Stratégie TDAE appliquée à la synthèse de candidats-médicaments

  2008cites this paper
• A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor.

  2007cites this paper
• Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5.

  2006cites this paper
• Anthracyclines as effective anticancer drugs

  2006cites this paper
• Ethonafide-Induced Cytotoxicity Is Mediated by Topoisomerase II Inhibition in Prostate Cancer Cells

  2006cites this paper
• A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor

  2006cites this paper
• Synthesis, spectroscopic and X-ray structure analyses of two N-[(3′-aryl) prop-2′-ynyl]-N,N′-1,2-phenylene di-p-tosylamides

  2006cites this paper
• Part 3: synthesis and biological evaluation of some analogs of the antitumor agents, 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid, and 2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid.

  2005cites this paper
• Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug–drug interactions

  2005cites this paper
• Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIα and β—Distinct mode of action of two derivatives

  2005cites this paper
• Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.

  2005cites this paper
• Activation of the Unfolded Protein Response Is Necessary and Sufficient for Reducing Topoisomerase IIα Protein Levels and Decreasing Sensitivity to Topoisomerase-Targeted Drugs

  2005cites this paper
• Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

  2005cites this paper
• Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4.

  2005cites this paper
• Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ

  2005cites this paper
• Development of new topoisomerase II-targeting compounds as candidate anticancer drugs

  2003cites this paper
• Understanding the action of drugs targeting TOP2: Yeast based systems for unraveling drug mechanisms

  2003cites this paper
• DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.

  2003cites this paper
• Design and development of novel DNA Topoisomerase inhibitors.

  2003cites this paper
• Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines

  2002cites this paper
• Chiral high-performance liquid chromatographic analysis of the enantiomers of XK469, a new antitumor agent, in plasma and urine.

  2002cites this paper
• Painting with a molecular brush: genomic/proteomic interfacing to define the drug action profile of novel solid-tumor selective anticancer agents.

  2002cites this paper
• DNA Topoisomerase II as a Target for Cancer Chemotherapy

  2002cites this paper
• Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30

  2002cites this paper
• Culprit and victim -- DNA topoisomerase II.

  2002cites this paper
• 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.

  2002cites this paper
• Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice

  2002cites this paper
• Cellular drug action profile paradigm applied to XK469.

  2002cites this paper
• 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.

  2002cites this paper
• Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIbeta poison in the rat.

  2002influential citation
• Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination

  2002cites this paper
• XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway

  2002cites this paper
• Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex.

  2002cites this paper
• Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

  2002cites this paper
• Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.

  2001cites this paper
• Catalytic inhibition of DNA topoisomerase IIα by sodium azide

  2001cites this paper
• Catalytic inhibition of DNA topoisomerase IIalpha by sodium azide.

  2001cites this paper
• The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.

  2001cites this paper
• Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).

  2001cites this paper
• Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor.

  2001cites this paper
• Topoisomerase II Poisoning by ICRF-193*

  2001cites this paper